BRRGF (Oncoinvent ASA) Moat Score: 0/10 (As of Jul. 09, 2026)


BRRGF Oncoinvent ASA BRRGF
36 GF Score
Price $97.09
GF Value $1,788.00
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Moat Score?

Oncoinvent ASA has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Oncoinvent ASA has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Oncoinvent ASA might have No Moat - No discernible moat.

Oncoinvent ASA  (OTCPK:BRRGF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Oncoinvent ASA Moat Score Related Terms

BRRGF
36GF Score
Oncoinvent ASA BRRGF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (BRRGF) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of $97.09 is trading 94.6% below its estimated GF Value™ of $1,788.00.

Key valuation signals for BRRGF:

  • Moat Score: 0
  • GF Value™: $1,788.00 vs. price of $97.09 (94.6% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the BRRGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for BRRGF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.09
Price
$1,788.00
GF Value